Celgene has had a rocky last couple of months, with its share price dropping from $146 to $87 since October last year. This time, the blame game seems to fall on Chief Operating Officer, Scott Smith.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
Singlera Genomics, a non-invasive genetic diagnostics company that focuses on early-stage cancer detection, has secured a $60 million Series A+ financing.
Searching for new drugs requires patience, skill and, of course, money. Now, researchers have developed a method to examine millions of potential self-produced drug candidates in one go.
Head of the FDA, Scott Gottlieb has suggested some ways in which pharma giants could rethink their business models, to help unproductive drugmakers.
Experts have revealed that cut-price copies of an expensive Roche biotech drug for blood cancer have taken 80% of the British market since launching last year, saving the healthcare system £80 million a year.
Going against industry trend of backing out of the neuroscience field, is Celgene, who is about to put down a potential $2.2 million to gain options on three Prothena drug candidates.
Healthcare tech startup Theranos was riding high back in 2014. But when a reporter raised questions, its media reps circled the wagons.
Chinese pharmaceutical companies are proving their place in the US generic drugs market, with a rising number of approvals for copycat medicines almost doubling in the past year.
FDA Commissioner, Scott Gottlieb has critiqued health insurers, as he homes in on the increasingly popular target of rebates in the drug pricing debate.